Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases.

Theodosiou Z, Kasampalidis IN, Karayannopoulou G, Kostopoulos I, Bobos M, Bevilacqua G, Aretini P, Starita A, Lyroudia K, Pitas I.

Breast. 2008 Feb;17(1):80-4. Epub 2007 Sep 21.

PMID:
17889539
[PubMed - indexed for MEDLINE]
2.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group.

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

PMID:
20661914
[PubMed - indexed for MEDLINE]
Free Article
3.

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C.

Diagn Pathol. 2013 Feb 4;8:17. doi: 10.1186/1746-1596-8-17.

PMID:
23379971
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Maximizing the response to Herceptin therapy through optimal use and patient selection.

Leyland-Jones B.

Anticancer Drugs. 2001 Dec;12 Suppl 4:S11-7. Review.

PMID:
11989522
[PubMed - indexed for MEDLINE]
5.

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.

Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J.

J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.

PMID:
17412870
[PubMed - indexed for MEDLINE]
6.

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.

Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF.

Breast Cancer Res Treat. 2005 Sep;93(1):3-11.

PMID:
16184453
[PubMed - indexed for MEDLINE]
7.

Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.

Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G.

J Pathol. 2005 Apr;205(5):577-84.

PMID:
15732132
[PubMed - indexed for MEDLINE]
8.

Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.

Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL.

Arch Pathol Lab Med. 2008 Oct;132(10):1635-47. doi: 10.1043/1543-2165(2008)132[1635:COQIWC]2.0.CO;2.

PMID:
18834223
[PubMed - indexed for MEDLINE]
9.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.

PMID:
21594665
[PubMed - indexed for MEDLINE]
10.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
[PubMed - indexed for MEDLINE]
11.

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

Desmedt C, Sperinde J, Piette F, Huang W, Jin X, Tan Y, Durbecq V, Larsimont D, Giuliani R, Chappey C, Buyse M, Winslow J, Piccart M, Sotiriou C, Petropoulos C, Bates M.

Diagn Mol Pathol. 2009 Mar;18(1):22-9. doi: 10.1097/PDM.0b013e31818ebc69.

PMID:
19214112
[PubMed - indexed for MEDLINE]
12.

[Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].

Ying JM, Liu XY, Guo L, Xie YQ, Lü N.

Zhonghua Bing Li Xue Za Zhi. 2012 May;41(5):296-300. doi: 10.3760/cma.j.issn.0529-5807.2012.05.003. Chinese.

PMID:
22883666
[PubMed - indexed for MEDLINE]
13.

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ.

Mod Pathol. 2007 May;20(5):584-91. Epub 2007 Mar 30.

PMID:
17396141
[PubMed - indexed for MEDLINE]
Free Article
14.

Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.

Tubbs RR, Pettay JD, Swain E, Roche PC, Powell W, Hicks DG, Grogan T.

Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):436-40.

PMID:
17122642
[PubMed - indexed for MEDLINE]
15.

HER2 status in breast cancer determined by IHC and FISH: comparison of the results.

Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.

Pol J Pathol. 2004;55(4):165-71.

PMID:
15757204
[PubMed - indexed for MEDLINE]
16.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M.

Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.

PMID:
11770175
[PubMed - indexed for MEDLINE]
17.

[HER2 ASCO guidelines. The answer to everything?].

Burandt E, Sauter G.

Pathologe. 2010 Oct;31 Suppl 2:285-91. doi: 10.1007/s00292-010-1348-4. German.

PMID:
20740285
[PubMed - indexed for MEDLINE]
18.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
[PubMed - indexed for MEDLINE]
19.

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.

Breast Cancer Res. 2009;11(4):R50. doi: 10.1186/bcr2339. Epub 2009 Jul 22.

PMID:
19624808
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Concordance between central and local laboratory HER2 testing from a community-based clinical study.

Reddy JC, Reimann JD, Anderson SM, Klein PM.

Clin Breast Cancer. 2006 Jun;7(2):153-7.

PMID:
16800975
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk